Immtech Completes Enrollment In Phase III Pivotal Trial Of Pafuramidine For African Sleeping Sickness

... Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that it has completed enrollment in a Phase III pivotal trial of its oral drug candidate, pafuramidine maleate (pafuramidine), to treat first-stage patients (those with no evidence of central nervous system involvement) for African trypanosomiasis, also known as African sleeping sickness. [click link for full article] ...